U.S. markets closed

Denali Therapeutics Inc. (DNLI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
75.06+0.06 (+0.08%)
At close: 4:00PM EDT
76.01 +0.95 (1.27%)
After hours: 06:36PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close75.00
Open74.96
Bid65.08 x 800
Ask80.00 x 1300
Day's Range74.27 - 76.92
52 Week Range22.36 - 93.94
Volume371,330
Avg. Volume511,693
Market Cap9.097B
Beta (5Y Monthly)1.90
PE Ratio (TTM)152.56
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-12% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Is Denali Therapeutics Inc. (DNLI) Up 10.7% Since Last Earnings Report?
    Zacks

    Why Is Denali Therapeutics Inc. (DNLI) Up 10.7% Since Last Earnings Report?

    Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • 10 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson
    Insider Monkey

    10 Best Pharmaceutical Stocks to Buy According to Billionaire Kerr Neilson

    In this article we will take a look at the 10 best pharmaceutical stocks to buy according to billionaire Kerr Neilson. You can skip our detailed analysis of the pharmaceutical industry’s outlook for 2021 and some of the major growth catalysts for pharmaceutical stocks and go directly to the 5 Best Pharmaceutical Stocks to Buy […]

  • Biden's Budget May Boost These 3 Biotechs
    Motley Fool

    Biden's Budget May Boost These 3 Biotechs

    In President Joe Biden's first proposed budget to Congress, he requested authorization for spending increases in a number of areas. Specifically, the president proposed a new agency within the National Institutes of Health (NIH) with a directive to cure some of the most pressing diseases of our time, including Alzheimer's disease. If the budget is adopted, biotechs like Denali Therapeutics (NASDAQ: DNLI), Cassava Sciences (NASDAQ: SAVA), and Eli Lilly (NYSE: LLY) could find themselves with more resources than ever in a market that is estimated to reach $13 billion by 2028.